were not signifi cantly elevated in the colonic mucosa of non-PI-IBS patients, and did not correlate with symptoms. Thus, these fi ndings do not support that colonic mucosal infl ammation consistently has a primary role in these patients. However, the fi nding of decreased IL-10 mRNA expression may be a possible biomarker of IBS and warrants further investigation.
INTRODUCTION
Low-grade infl ammation or immune activation of the gut has been proposed to have a role in irritable bowel syndrome (IBS) pathophysiology ( 1 -4 ) , and specifi cally in the development of visceral hypersensitivity and epithelial dysfunction ( 5 -7 ) . Reported fi ndings in post-infectious IBS (PI-IBS) as well as in non-PI-IBS or unselected patients generally support this hypothesis. Th e strongest evidence is from studies of patients with PI-IBS, which have shown increased number colonic lamina propria T lymphocytes ( 8 ) , and increased mRNA levels of the pro-infl ammatory cytokine interleukin-1 β (IL-1 β ) in the rectal mucosa compared with patients who do not develop IBS symptoms aft er a gastroenteritis ( 9 ) . However, fi ndings have been less consistent in non-PI-IBS patients and unselected patients, particularly in regards to possible correlations of such fi ndings with IBS symptoms. Th is may be in part related to sample size and increased heterogeneity. Additionally, although IBS
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Immune Markers in IBS occurs in both men and women, most of the studies conducted in IBS have been performed in female patients without a matched sex distribution in the control groups. However, a female predisposition to PI-IBS ( 10 ) and sex diff erences in the physiologic disturbances in IBS, including colonic mucosal mast cell numbers of IBS ( 11 ) , suggest that sex diff erences in immune activation may exist in IBS.
In unselected IBS patients, studies have reported increased activated T cells in the blood ( 12 ) and increased T lymphocytes ( 3, 11, 13 ) mast cells ( 2,4,11,13 -16 ) , and toll-like receptor expression ( 17 ) within the colonic mucosa. Barbara et al. ( 2 ) found that the number of mast cells in close proximity to sensory neurons positively correlated with severity and frequency of abdominal pain / discomfort. However, other studies have found similar or lower mast cell numbers in colonic or rectal mucosa in IBS patients compared with healthy controls ( 3, 18, 19 ) . In one of these studies, IBS patients had fewer mast cells in the rectum and descending colon and decreased tryptase release regardless of the presence of visceral hypersensitivity in comparison to control subjects ( 18 ) .
Similar to studies of infl ammatory cells in non-PI-IBS and unselected patients, levels of serum cytokines have generally been increased but specifi c cytokines studied and positive fi ndings have diff ered ( 4,12,20 -22 ) . Th ere is a lack of evidence to support higher mucosal mRNA or protein levels of pro-infl ammatory cytokines in non-PI-IBS ( 23, 24 ) . In female IBS patients, Macsharry et al. ( 23 ) demonstrated lower or normal mRNA expression and protein levels of pro-infl ammatory cytokines, including IL-1 β and IL-6, in colonic tissue from IBS but decreased expression of the anti-infl ammatory cytokines IL-10 and TGF-β (transforming growth factor-β ) compared with healthy females. In contrast, patients with active infl ammatory bowel disease (IBD) had increased chemokines and pro-infl ammatory cytokines. Furthermore, we have previously shown lower mRNA levels of IL-2, IL-6, and IL-10 from sigmoid colon biopsies in female IBS patients with diarrhea (IBS-D) compared with healthy females although the two groups were relatively small in size ( 24 ) .
Studies in IBD have demonstrated that active infl ammation is associated with upregulation of mucosal signaling systems, including the corticotropin releasing factor (CRF) ( 25 ) , neurokinin (NK) ( 26 ) , and serotonin (5-HT) systems located in enterochromaffi n (EC) cells ( 27 ) . Several studies indicate increased expression of the CRF ligand -receptor system in the colonic mucosa of IBD patients ( 28 -30 ) . Increased expression of NK-1R and altered serotonin signaling have been reported in patients with IBD and in animal models of colitis ( 26, 31 ) . For example, in severe UC (ulcerative colitis), EC cell counts, mucosal 5-HT content, and mRNA expression of tryptophan hydroxylase 1 and SERT (serotonin reuptake transporter) were decreased ( 32 ) . In contrast, increased EC cell counts have been demonstrated in rectal biopsies of PI-IBS patients ( 8, 14 ) , while normal counts have been found in unspecifi ed or non-PI-IBS ( 14, 32, 33 ) . EC cell counts were found to be either normal (non-severe) or decreased (severe) in ulcerative colitis ( 32 ) . However, mucosal 5-HT content and mRNA expression of tryptophan hydroxylase 1 and the serotonin transporter (SERT) were decreased. It has been hypothesized that SERT expression decreases aft er intestinal infl ammation, resulting in amplifi cation of serotonergic signaling that exerts an increased infl ammatory response ( 27 ) .
Despite the large body of published data, uncertainty remains regarding the following questions: (i) Is the colonic mucosa the source of reported immune activation? (ii) Are IBS symptoms correlated with mucosal immune activation? (iii) Are reported fi ndings related to coexistent psychological symptoms? (iv) Do the reported fi ndings diff er between men and women? Th e current study, performed in a well-characterized sample of male and female IBS patients and matching healthy controls, was aimed to address these questions. A comprehensive set of immune markers, and markers previously shown to be upregulated in association with mucosal infl ammation were measured in serum and mucosal biopsies to test the following hypotheses: (i) IBS patients show increased mucosal or systemic expression of pro-infl ammatory cytokines, and increased numbers of mucosal lymphocytes and mast cells compared with controls; (ii) IBS patients show altered expression of neuropeptide and neuroendocrine markers (CRF and NK signaling systems, EC and enteroendocrine (EE) cells), which are oft en associated with mucosal infl ammation; and (iii) these peripheral changes correlate with subjective symptoms of IBS.
METHODS
Study subjects
Forty-fi ve IBS patients (26 women and 19 men) and 41 healthy controls (22 women and 19 men) participated in the study. Patients between the ages of 18 and 55 who met entry criteria were recruited from the specialty clinic and community advertisements although subjects were not consecutively enrolled. Age was limited to 55 years since age can aff ect immune response ( 34 ) . All IBS patients met the Rome II diagnostic criteria for IBS ( 35 ) . Th e diagnosis was confi rmed by a gastroenterologist with expertise in IBS (L.C.). Bowel habit subtypes of IBS-D and IBS with constipation (IBS-C) were based on the Rome II subclassifi cation criteria. Patients with IBS who did not meet either IBS-D or IBS-C criteria and had a history of alternating diarrhea and constipation were considered to have IBS-A / M. Healthy controls between the ages of 18 -55 were recruited by newspaper or internet advertisement from the community, and they did not have a history of IBS, other chronic pain conditions, infectious or infl ammatory disorders, or psychiatric illness, and were not taking centrally acting drugs (anxiolytics, narcotics, anti-depressants). None of the subjects had taken corticosteroids or immunosuppressive agents that could aff ect neuroendocrine and immune function in the past 2 months or had a current history of tobacco or alcohol abuse. For premenopausal women not taking oral contraceptive agents or provera, menstrual cycle phase was determined by the count forward / backward method (menses: fi rst 3 days of menses; follicular: days 4 -14; luteal: day 14 to onset of menses). Serum progesterone was collected to help confi rm cycle phase. Subjects were compensated $ 25 for an initial screening visit and $ 125 for completing the fl exible sigmoidoscopy and blood draws for cytokine levels.
Symptom measures
Validated questionnaires were used for IBS symptoms (UCLA [University of California Los Angeles] Bowel Symptom Questionnaire)
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Chang et al. ( 36 ) , depression and anxiety (HAD [Hospital Anxiety and Depression] scale) ( 37 ) , and disease-specifi c quality of life assessment ( 38 ) . IBS patients rated the intensity of their IBS symptoms for the past 24 h. Subjects were screened by interview for psychiatric disorders using the structured clinical interview for the DSM-IV (SCID) by a licensed therapist (M.M.) ( 39 ) .
Study protocol
A fl exible sigmoidoscopy to at least 40 cm from the anal verge was performed in the Medical Procedures Unit between 1200 and 1400 hours. Subjects were instructed to use two tap-water enemas as the bowel preparation. Before the sigmoidoscopy, blood samples were drawn for cytokine levels and progesterone level (to confi rm menstrual cycle phase). During the sigmoidoscopy, 15 sigmoid colon biopsies were taken at 30 cm from the anal verge.
Serum cytokines
Th e following cytokines were measured in serum collected from study subjects: IL-1 β , IL-6, IL-8, IL-10, IL-12, and TNF-α (tumor necrosis factor-α ). In all, 25 μ l of MSD (Meso Scale Discovery; Gaithersburg, MD) assay diluent was added into each well of a 96-well plate. Th e plate was then incubated for 30 min with vigorous shaking (300 -1,000 r.p.m.) at room temperature. In all, 25 μ l of prepared standard (ranging from 2,500 to 0 pg / ml) or serum sample was dispensed into a separate well of the MSD plate and incubated for 2 h with vigorous shaking (300 -1,000 r.p.m.) at room temperature. Th e plate was then washed 3 × with PBS (phosphate-buff ered saline) + 0.05 % Tween-20. In all, 25 μ l of detection antibody solution was added into each well of the MSD plate, the plate was sealed and incubated for another 2 h with vigorous shaking (300 -1,000 r.p.m.) at room temperature. Followed by washing 3 × with PBS + 0.05 % Tween-20, 150 μ l of 2 × read buff er T was then added to each well of the MSD plate. Th e plate was immediately read on the SECTOR(r) Imager (Meso Scale Discovery; Gaithersburg, MD).
Determination of mRNA levels using real-time quantitative reverse transcriptase polymerase chain reaction (TaqMan assay)
For detection of cytokines, CRF-related ligands (CRF; urocortin (Ucn) 1 -2), CRF 1 receptor (CRF 1 R) and CRF 2 receptor (CRF 2 R), NK peptides / receptors (TAC1, NK-1R, NK-2R), RNA isolated from sigmoid colon biopsy tissue was reverse transcribed into complementary deoxyribonucleic acid (cDNA) and real-time PCR (polymerase chain reaction) was performed using a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Details of the methodology have been previously described ( 40, 41 ) .
Two primers with amplicon lengths 61 and 113 were used to evaluate CRF 1 R mRNA levels. Th e number of PCR cycles, " Ct, " was normalized to arbitrary mRNA units by an 18- Colonic mucosal cellularity . Biopsy specimens were fi xed in buffered 10 % formalin. Paraffi n-embedded specimens were sliced in 4 μ m sections with a mictotome, and mounted on slides. Slides were baked at 60 ° C for at least 30 min to melt the paraffi n. Th e slides were deparaffi nized with xylene and rehydrated through graded ethanol. Endogenous peroxidase activity was blocked with 3 % hydrogen peroxide in methanol for 10 min (except for CD4 lymphocytes). An antigen retrieval technique was applied by boiling the slides for 25 min at 95 ° C in 0.01 M sodium citrate buff er, pH = 6.00. For mast cell tryptase (DakoCytomation, Carpinteria, CA; 1:500 dilution), proteinase K, Digest-all-4 enzyme was applied for 5 min at room temperature. Primary antibodies were applied at primary antibody concentration for primary antibody incubation time. Th e slides were incubated with primary antibodies to CD3 (Biocare Medical, Concord, CA; 1:50 dilution), CD4 (Th ermo Scientifi c, Waltham, MA; 1:10 dilution), and CD8 (DakoCytomation; 1:50 dilution) for T lymphocytes for 45 min. Th ey were subsequently incubated with labeled polymer (secondary antibody) anti-mouse, anti-rabbit for 30 min. Th e sections were treated with DAB (diaminobenzidine) for 10 min for visualization and then counterstained with hematoxylin. EC and EE cells were identifi ed by staining with antibodies to 5-HT (DakoCytomation; 1:100 dilution) and chromogranin A (CgA; DakoCytomation; 1:1,000 dilution), respectively, similarly as previously described ( 42 ) .
Scanning and analyses were performed through the Translational Pathology Core Laboratory at UCLA. Hematoxylin and eosin-stained slides were quality assured to be compatible study parameters including normal histology and adequate orientation. Counterstained immunohistochemically stained slides were quality assured for orientation, absence of lymphoid follicles and folding / crush artifacts in areas of analytical interest, in a manner identical to previously published ( 43 ) . Slides were analyzed using the Ariol SL-50 automated slide scanner (Applied Imaging, San Jose, CA) to quantify the amount of positive staining for each area of interest. A thresholded total area of detected signal for a given immunohistochemical stain was measured vs. slide area. Automated area measurements have been shown to strongly correlate with individual cells counts ( 43 ) . A 10 % manual count quality assurance was performed to reinforce the linear relationship of cellularity with area detection. Th resholds for each image were applied using the Ariol analytical soft ware based on multiple parameters: red blue green (RGB) algorithm optimized for the detection of DAB chromogen; shape and size restrictions to exclude subcellular and non-cellular structures were included. All analyses were performed with the MultiStain script. Th resholded classifi ers were customized for each stain. For assessing cytoplasmic / cell surface staining, the area of positive stain was calculated by applying color thresholds to detect positive brown pixels. Percent of positivity was determined by dividing the total positive stain area ( μ m 2 ) by the total area analyzed ( μ m 2 ) × 100. Th e pathologist (G.C.) overseeing the mucosal histology is an experienced GI (gastrointestinal) pathologist with extensive experience in mucosal endocrine and infl ammatory cells enumeration ( 42 -44 ).
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Statistical analysis
Comparisons between two groups were analyzed with MannWhitney U tests. We used a Bonferroni-adjusted signifi cance level of 0.0083 to account for IBS vs. control comparisons within sex for three types of immunological measures, that is, serum cytokines, colonic cytokines, and neuropeptides / receptors (CRF and NK measures) and cell counts. Spearman ' s rank correlation test was used where indicated to assess correlations between serum and colonic mucosal cytokine measures. In addition, Spearman ' s rank correlation test was used to assess correlations between immune measures and symptoms. Results are presented as mean ± standard error of the mean (s.e.m.). All analyses were performed using the publicly available R statistical soft ware (version 2.11.1) ( 45 ) .
Th e study was approved by the UCLA Institutional Review Board and was conducted in accordance with the institutional guidelines regulating human subjects research.
RESULTS
Clinical characteristics
Clinical characteristics of patients and control subjects are shown in Table 1 . While the IBS-D and IBS-A / M were evenly distributed among the men, the predominant bowel habit subtype in the women was IBS-C. None of the IBS patients had a history of PI-IBS, which has been defi ned as the new onset of IBS symptoms immediately following an acute illness characterized by vomiting, diarrhea, or a positive bacterial stool culture ( 46 ) . Compared with controls, IBS patients within the male and female groups had higher HAD anxiety and depression scores, even though scores were within the normal range. HAD anxiety ( P = 0.78) and depression scores ( P = 0.55) did not diff er signifi cantly between IBS males and females. Menstrual cycle phase and menopausal status were not signifi cantly different between female IBS patients and controls.
Serum and sigmoid colonic mucosal cytokines
Of the 86 study participants, blood samples for serum cytokine levels could only be collected in 73 participants (17 healthy males, 17 IBS males, 17 healthy females, and 22 IBS females). Th ere were no signifi cant diff erences in the serum levels of IL-1 β , IL-6, IL-8, IL-10, IL-12, and TNF-α between IBS and controls within males and females ( Figure 1a, b ) . With regard to sigmoid colonic mucosal cytokine mRNA expression, IL-1 β , IL-6, IL-8, IL-12, and TNF-α mRNA levels ( Figure 2a, b ) were similar between IBS patients and controls within males and females, and when these groups were combined ( P values ranged from 0.052 to 1.0). However, female patients had signifi cantly lower expression of the anti-infl ammatory cytokine IL-10 than female controls (18.0 ± 2.9 vs. 29.5 ± 4.0, P = 0.007; Figure 3 ). Th is diff erence remained signifi cant aft er controlling for menstrual cycle phase. Th ere was a trend for lower IL-10 mRNA expression in IBS vs. controls overall (17.5 ± 2.0 vs. 
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between the immune markers with disease-specifi c IBS quality of life domains.
Mucosal cell counts
Th ere were no signifi cant disease (IBS vs. controls) or bowel habit subgroup diff erences for CD3, CD4, and CD8 lymphocyte, or EE, EC, and mast cell counts ( P = 0.059 -0.892) ( Table 2 ). Representative images of female IBS-D and control colonic mucosa by CD4, mast cell, and EC cells immunohistochemistry are shown in Figure 4 .
22.9 ± 2.5, P = 0.073) but no diff erences within bowel habit subgroups. Colonic IL-10 mRNA levels were not diff erent between the male IBS and control subjects. None of the serum cytokine levels signifi cantly correlated with their respective colonic mucosal mRNA levels. Lower serum IL-10 levels correlated with higher ratings of symptom intensity in the overall group of IBS patients ( r = − 0.45, P = 0.006). No other immune measures correlated with IBS or psychological symptoms with the exception of a negative correlation between serum IL-12 and HAD depression symptom ratings ( r = − 0.42, P = 0.007). Th ere were no signifi cant correlations 
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Sigmoid colonic mucosal mRNA expression of CRF-and NK-related neuropeptides
In some subjects, CRF and NK neuropeptides were non-detectable. In all, 86 % of subjects had undetectable expression levels for CRF 1 R, 18 % for CRF ligand, 1 -6 % for Ucn 1 -2 and NK neuropeptides. Because of the low detection rate for CRF 1 R, we tried an additional marker set and obtained similar results. As a result, CRF 1 R was not analyzed due to few samples with detectable levels. NK-1R was expressed in all subjects and mRNA levels were signifi cantly lower in female patients compared with female controls (Mann -Whitney rank sum test P value = 0.008) ( Table 2 ; Figure 5 ). Th is diff erence remained signifi cant aft er controlling for menstrual cycle phase. Th ere was a trend for lower mRNA expression in IBS vs. controls overall (0.97 ± 0.1 vs. 1.8 ± 0.3, P = 0.054).
DISCUSSION
In this comprehensive comparison of immune markers from blood and sigmoid colonic tissue samples in well phenotyped male and female IBS patients and healthy controls, the main fi ndings of the study were (i) female patients had signifi cantly lower colonic mucosal IL-10 mRNA levels compared with healthy female controls, but levels did not correlate with IBS symptoms; (ii) lower serum IL-10 levels correlated with higher ratings of symptom intensity in IBS patients; (iii) no group diff erences in serum cytokine levels were detected; (iv) colonic mucosal NK-1R mRNA expression was signifi cantly lower in female patients compared with healthy females; and (v) no signifi cant diff erences in the other immune or neuroendocrine markers were found between patients and controls.
Mucosal or systemic expression of cytokines and mucosal lymphocytes and mast cells in IBS and controls
We did not fi nd increased colonic mucosal expression of proinfl ammatory cytokines but did fi nd lower colonic mucosal mRNA expression of the anti-infl ammatory cytokine IL-10 in IBS females compared with healthy females. In addition, serum IL-10 levels negatively correlated with IBS symptom ratings. Th e anti-infl ammatory mediator IL-10 inhibits cytokine synthesis ( 47 ) and therefore, decreased IL-10 levels could predispose to increased mucosal cytokine production during infections or other mucosal insults. Our fi nding is supported by similar reports in the only two previous studies that compared cytokine levels in the sigmoid colonic mucosa in IBS and healthy controls ( 23, 24 ) . Both studies only assessed females and found lower IL-10 mRNA expression in IBS patients than controls and failed to detect increases in proinfl ammatory cytokines despite enrolling IBS females with diff erent bowel habit subtypes ( 23, 24 ) . In one of these studies, cytokine protein analysis in colonic tissue confi rmed that pro-infl ammatory cytokine levels were similar in IBS and healthy controls, and lower compared to patients with IBD ( 23 ) . A possible role of reduced IL-10 expression in IBS pathophysiology is also supported by reported fi ndings in 111 IBS patients and 162 healthy controls in which the low producer IL-10 genotype was signifi cantly more prevalent in IBS patients compared with healthy controls ( 48 ) . In addition, a recent study found that baseline and stimulated levels of IL-10 in the blood were signifi cantly lower in children with IBS vs. healthy children ( 49 ) . Future studies will need to determine the mechanism involved in the reduction in IL-10 expression, and why this alteration is more prevalent in female patients.
Th e fi nding of similar levels of serum cytokines in IBS and controls in our study diff ers from other reports where elevated levels of pro-infl ammatory cytokines in blood or secreted from stimulated peripheral blood mononuclear cells have been reported ( 12, 20, 21, 50, 51 ) . Kindt et al. ( 52 ) reported that patients with IBS or other functional GI disorders had a shift toward a Th 2 plasma cytokine profi le. We measured levels of the Th 2 cytokines, IL-6 and IL-10, and neither was altered in the blood but IL-10 mRNA expression was lower in the colon. We did not fully address the Th 2 cytokine group in this study, but reduced expression of IL-10 suggests that a shift toward a Th 2 pattern may be occurring in the colonic mucosa in IBS. It is also possible that IBS patients have a more " hyperresponsive " immune system to stimuli (e.g., stress, antigens) than healthy controls. Factors that infl uence the reactivity of the immune system may diff er between studies and contribute to the heterogeneity of subject data. Previously reported studies have not measured cytokine levels from the blood and colonic tissue in the same subjects. Th e lack of correlation of cytokine levels in the blood and colonic tissue suggest that the cytokine levels in the blood in IBS and controls may not be primarily derived from the gut. Increased levels of systemic pro-infl ammatory cytokines have been reported in association with psychological and physical stressors, including depression and strenuous exercise ( 53, 54 ) . Cytokines measured in the blood can be derived from multiple sources, including the spleen, liver, heart, gut, and fat tissue and from skeletal muscle ( 55 -57 ) . Acting alone or in conjunction with components of the stress system, cytokines can induce fever, sleepiness, fatigue, loss of appetite, and decreased libido ( " sickness behavior " ) ( 53 ) . Th us, it is not surprising that increased blood levels of the pro-infl ammatory cytokines, IL-1 β , IL-6, and IL-8, but not IL-10 were found in female IBS patients with extraintestinal comorbidities (fi bromyalgia, chronic fatigue syndrome, and premenstrual syndrome) compared with controls ( 58 ). In our study, only three of the IBS females had 
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Expression of neuropeptide and neuroendocrine markers (CRF, NK, and 5-HT signaling systems) that are associated with mucosal infl ammation
Th is is the fi rst study that has comprehensively measured colonic mucosal mRNA expression of CRF and NK receptors and ligands in IBS patients. NK-1R mRNA levels were signifi cantly lower in female patients compared with controls. Interestingly, chronic water avoidance stress in rats, which induces sustained visceral hyperalgesia, was associated with decreased expression of NK-1R mRNA and protein in the distal colon ( 60 ). It is not clear why there is reduced expression of NK-1R in the colon, but it may be related to chronic engagement of stress systems. Cottrell et al. ( 61 ) demonstrated that chronic stimulation with substance P induces ubiquitination of the NK-1R, which mediates its degradation and downregulation. Both central and peripheral NK and CRF signaling system have been characterized, with the central systems being engaged by psychosocial stressors ( 62 ) , and the peripheral systems being engaged in response to tissue irritation and mucosal infl ammation ( 25, 26 ) . In our study, CRF 1 R mRNA expression was below detection limits in most subjects and therefore could not be adequately compared between IBS and controls. If mucosal infl ammation were present in IBS, higher expression of these neuropeptides compared with controls would be expected. Activation a history of a coexistent functional pain syndrome (fi bromyalgia, interstitial cystitis, and myofascial pain condition).
With the exception of lower colonic IL-10 mRNA levels in females with IBS, the lack of diff erences in cytokine levels between patients and controls is supported by the fi nding of similar colonic mucosal cellularity, even when comparing within each sex. Th ese results are in apparent contrast to previous studies, which have demonstrated higher numbers of colonic mucosal lymphocytes ( 3, 11, 13 ) and mast cells ( 2, 11, 13, 15, 16 ) in IBS. However, with respect to mast cell numbers, our fi ndings are congruent with studies by Chadwick et al. ( 3 ), Klooker et al. ( 18 ) , and Cenac et al. ( 19 ) , which did not detect diff erences between IBS patients and controls. Th ere may be several reasons to explain these diff erences, including subject heterogeneity, the location of the tissue collected, and the methodology of determining cell counts. Alternatively, there could be only a small diff erence in mast cell counts between IBS patients and controls, requiring very large studies or meta-analyses to consistently detect the diff erence. It is important to note that Klooker et al. ( 18 ) found that the mast cell stabilizer antagonist ketotifen reduced IBS symptoms. While this suggests that ketotifen could be exerting its benefi cial eff ect on symptoms by decreasing mast cell activity rather than number, non-specifi c sedative eff ects of the drug may also be involved. Studies indicate that increased levels of tryptase and histamine, which are infl ammatory mediators released during mast cell degranulation, in colonic mucosal tissue collected from IBS patients activate sensory aff erent nerves Signifi cant values as determined by Mann -Whitney rank sum analysis with a level of signifi cance set at P < 0.0083.
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Immune Markers in IBS of CRF and NK signaling systems in the gut has been associated with activation of a pro-infl ammatory response, both in animal models of colitis and in patients with IBD ( 25, 26 ) . CRF and CRF receptor expression is increased at the gene and protein levels in the intestine of animal models of intestinal infl ammation ( 63, 64 ) . Furthermore, both CRF-defi cient and CRF 2 R-defi cient mice showed reduced intestinal infl ammatory responses. Several studies have demonstrated increased CRF, Ucn 1, Ucn 2, and CRF 2 R expression in the colonic mucosa of IBD patients ( 28 -30 ) , while studies in experimental models of intestinal infl ammation show that blockade or genetic defi ciency of these receptors are associated with reduced intestinal infl ammatory responses ( 65 -68 ) . In the colonic mucosa of IBD patients, increased numbers of CRF-immunoreactive macrophages and EC cells and increased Ucn expression in lamina propria mononuclear cells were demonstrated ( 26 ) . Similarly, substance P, NK-1R, and NK-2R expression were increased in colonic tissue of patients with IBD in most, but not all, studies ( 26, 31 ).
In the current study, no diff erences in EC or EE cell counts were found between patients and controls. While EC and EE cell counts were found to be increased in PI-IBS ( 8, 14, 69 ) , EC cells were not increased in unselected IBS patients ( 14, 32, 33 ) . Our results are similar to the latter studies, which would be expected since our sample did not contain any PI-IBS patients. Th ese similar fi ndings occurred despite mucosal sampling from the rectum in two of these studies ( 14, 32 ) , small intestine in the other ( 33 ) , and from the sigmoid colon in our study. Although EC cell hyperplasia has been demonstrated in both animal and human enteric infection studies, it is not a universal response to infection ( 1 ) .
Taken together, the lack of increased immune cellularity, proinfl ammatory cytokines and mRNA expression in the sigmoid 3 Elevated basal and stimulated cytokine levels in the blood have been reported in some but not all IBS studies.
3 No study has measured cytokine levels in the blood and colonic mucosa in the same IBS patients.
3 Sex differences have been reported in IBS, including colonic mucosal mast cell counts.
WHAT IS NEW HERE
3 Interleukin-10 (IL-10) mRNA expression in the sigmoid colon mucosa is decreased in female irritable bowel syndrome (IBS) patients compared with female controls, but there is no difference in males. This is a potential biomarker for IBS.
colonic mucosa of CRF-and NK-related neuropeptides in our IBS sample fails to support a signifi cant pro-infl ammatory state in non-PI-IBS. However, the possibility that there is an enhanced innate immunity to pathogens as suggested by the recent fi nding of abnormal toll-like receptor expression in the colonic mucosa of IBS ( 17 ) is intriguing and requires further study.
Sex differences
Th e lack of fi ndings in IBS males further supports the role of sex diff erences in IBS ( 70 ) . In previous studies, the gender distribution diff ered between control and IBS groups with most of the IBS patients being female. Enrolling similar numbers of males and females is important because sex diff erences in lymphocytes and mast cells exist in IBS ( 11 ) . It is possible that these sex diff erences contribute to the fact that female sex is an independent risk factor of developing PI-IBS ( 10 ). Th ese fi ndings can in part be due to estrogen ' s infl uence on pro-infl ammatory and anti-infl ammatory pathways ( 71, 72 ) . Our study has limitations. Our colonic mucosal fi ndings are limited to the sigmoid colon and it is possible that there are regional diff erences, such as more proximal regions of the colon or the small bowel. While cytokine mRNA expression was measured in the colonic mucosa, there was no measurement of colonic cytokine protein levels. Although EC cell counts were performed, we did not measure mucosal 5-HT content or SERT expression. Th e latter has been shown to be decreased in IBD in the setting of normal (non-severe UC) or decreased (severe UC) EC cell counts ( 32 ) . In our study, colonic mucosal mast cell and EC cell counts were similar in IBS and controls, but we did not perform functional assays of mediators (e.g., tryptase) released from cultured colonic biopsies on activation of aff erent nerves as has been previously described in IBS ( 5, 6 ) . In addition, measurements of the expression of neuropeptides and their respective receptors do not take into account if they are expressed on the cell surface or have been internalized. Finally, the heterogeneity of IBS patients and the disease complexity may result in small eff ect sizes that require hundreds to thousands of patients to detect reliably. Th us, although our patients have been carefully phenotyped and our study is comparable in size to other reported studies addressing this question, additional much larger studies are needed to confi rm our results.
In summary, we have demonstrated lower IL-10 mRNA expression in the colonic mucosa in IBS females compared with healthy females, suggesting a possible pathogenic role of IL-10 in IBS. However, the lack of signifi cant fi ndings in all other immunerelated measures in a relatively large number of IBS patients compared with controls questions the hypothesis that colonic mucosal infl ammation has a primary role in the pathogenesis of non-PI-IBS. Further studies are needed to confi rm these results.
